Chunghwa Chemical Synthesis & Biotech Co Ltd (TW:1762) — Stock Price
Chunghwa Chemical Synthesis & Biotech Co Ltd (TW:1762) is currently trading at NT$36.60 TWD, up 2.38% today. Over the past 52 weeks, shares have ranged between NT$24.30 and NT$42.30. This page tracks Chunghwa Chemical Synthesis & Biotech Co Ltd's live share price on the TW exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 1762 company net worth.
Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Chunghwa Chemical Synthesis & Biotech Co Ltd's daily closing share price and trading volume on the TW exchange over the past year, giving a clear view of recent price momentum and liquidity.
Chunghwa Chemical Synthesis & Biotech Co Ltd Income Statement — Revenue, Profit & Earnings by Year
Chunghwa Chemical Synthesis & Biotech Co Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | NT$804.88 Million | NT$1.35 Billion | NT$2.09 Billion | NT$2.12 Billion | NT$1.93 Billion |
| Cost of Revenue | NT$813.74 Million | NT$953.06 Million | NT$1.33 Billion | NT$1.16 Billion | NT$985.31 Million |
| Gross Profit | NT$-8.86 Million | NT$394.32 Million | NT$757.31 Million | NT$961.76 Million | NT$949.39 Million |
| Research & Development | NT$168.35 Million | NT$205.84 Million | NT$242.70 Million | NT$244.79 Million | NT$252.67 Million |
| SG&A | NT$142.33 Million | NT$86.38 Million | NT$104.63 Million | NT$109.31 Million | NT$95.23 Million |
| Total Operating Expenses | NT$310.67 Million | NT$387.98 Million | NT$757.31 Million | NT$516.57 Million | NT$492.57 Million |
| Operating Income | NT$-319.54 Million | NT$6.34 Million | NT$280.81 Million | NT$574.67 Million | NT$519.28 Million |
| EBITDA | NT$-128.19 Million | NT$277.66 Million | NT$545.93 Million | NT$743.72 Million | NT$651.27 Million |
| EBIT | NT$-319.54 Million | NT$78.51 Million | NT$352.93 Million | NT$574.67 Million | NT$519.28 Million |
| Interest Expense | NT$16.73 Million | NT$21.29 Million | NT$19.44 Million | NT$9.71 Million | NT$3.32 Million |
| Income Before Tax | NT$-255.68 Million | NT$57.22 Million | NT$333.49 Million | NT$583.30 Million | NT$497.61 Million |
| Income Tax Expense | NT$-11.83 Million | NT$4.19 Million | NT$68.58 Million | NT$117.17 Million | NT$96.56 Million |
| Net Income | NT$-243.85 Million | NT$53.03 Million | NT$264.91 Million | NT$465.87 Million | NT$400.78 Million |
Chunghwa Chemical Synthesis & Biotech Co Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Chunghwa Chemical Synthesis & Biotech Co Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | NT$4.32 Billion | NT$4.76 Billion | NT$5.17 Billion | NT$4.56 Billion | NT$4.38 Billion |
| Total Current Assets | NT$1.06 Billion | NT$1.44 Billion | NT$1.79 Billion | NT$1.45 Billion | NT$1.36 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | NT$10.70 Million | NT$-10.70 Million | NT$-10.70 Million |
| Net Receivables | NT$96.61 Million | NT$199.30 Million | NT$248.37 Million | NT$312.34 Million | NT$379.88 Million |
| Inventory | NT$717.94 Million | NT$969.00 Million | NT$1.21 Billion | NT$819.95 Million | NT$753.85 Million |
| Property, Plant & Equipment | — | — | — | — | NT$1.87 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | NT$1.23 Billion | NT$1.41 Billion | NT$1.82 Billion | NT$1.37 Billion | NT$1.49 Billion |
| Total Current Liabilities | NT$356.71 Million | NT$425.29 Million | NT$831.41 Million | NT$614.18 Million | NT$635.17 Million |
| Long-term Debt | NT$600.00 Million | NT$700.00 Million | NT$700.00 Million | NT$500.00 Million | NT$600.00 Million |
| Net Debt | NT$589.42 Million | NT$635.89 Million | NT$939.54 Million | NT$303.93 Million | NT$558.30 Million |
| Total Stockholder Equity | NT$3.09 Billion | NT$3.36 Billion | NT$3.35 Billion | NT$3.19 Billion | NT$2.89 Billion |
| Retained Earnings | NT$1.45 Billion | NT$1.72 Billion | NT$1.74 Billion | NT$1.67 Billion | NT$1.34 Billion |
Chunghwa Chemical Synthesis & Biotech Co Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Chunghwa Chemical Synthesis & Biotech Co Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | NT$142.61 Million | NT$467.65 Million | NT$-77.50 Million | NT$733.78 Million | NT$219.18 Million |
| Capital Expenditures | NT$62.33 Million | NT$104.69 Million | NT$450.00 Million | NT$376.18 Million | NT$405.45 Million |
| Free Cash Flow | NT$80.28 Million | NT$362.96 Million | NT$-517.83 Million | NT$357.60 Million | NT$-186.27 Million |
| Investing Cash Flow | NT$-61.80 Million | NT$-100.10 Million | NT$-461.32 Million | NT$-376.18 Million | NT$-802.75 Million |
| Financing Cash Flow | NT$-86.03 Million | NT$-415.72 Million | NT$496.57 Million | NT$-253.32 Million | NT$630.62 Million |
| Dividends Paid | NT$-14.74 Million | NT$-62.05 Million | NT$-100.83 Million | NT$100.83 Million | NT$116.34 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | NT$191.35 Million | NT$199.16 Million | NT$193.00 Million | NT$169.05 Million | NT$131.99 Million |
| Change in Cash | NT$-5.84 Million | NT$-47.29 Million | NT$-31.05 Million | NT$105.36 Million | NT$46.62 Million |
Chunghwa Chemical Synthesis & Biotech Co Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Chunghwa Chemical Synthesis & Biotech Co Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 31, 2026 | -2.55 | -0.20 | -1175.00% |
| Nov 14, 2025 | -0.77 | -0.22 | -250.00% |
| Aug 04, 2025 | — | — | — |
| May 06, 2025 | — | — | — |
| Mar 10, 2025 | — | — | — |
| Nov 11, 2024 | -0.11 | — | — |
| Aug 13, 2024 | 0.27 | 0.66 | -59.09% |
| May 15, 2024 | 0.52 | 0.15 | +246.67% |